Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 4:14 AM
Ignite Modification Date:
2025-12-25 @ 4:14 AM
NCT ID:
NCT03004820
Eligibility Criteria:
Inclusion Criteria:
1. Eighteen years old or older of any gender or race;
2. Diagnosed with a non-cardiogenic MIS/TIA within 14 days; MIS is defined by an ischemic stroke of score of 3 or less on the NIHSS at the time of inclusion, TIA is defined as neurologic deficit attributed to focal brain ischemia, with symptoms resolution within 24 h of symptom onset, Symptom onset is defined by the "last see normal" principle;
3. Stable vital signs, normal cardiac, hepatic and renal functions;
4. Able to consent by himself/herself or by legally authorized representative.
Exclusion Criteria:
1. Diagnosis of hemorrhage or other pathology, such as vascular malformation, tumor, abscess or other non-vascular diseases, based on brain CT or MRI;
2. Modified Rankin Scale score \> 2 at inclusion;
3. Received iv. recombinant tissue plasminogen activator (rtPA) therapy or interventional treatment for the current event;
4. Contradiction for aspirin or clopidogrel (known allergy, severe asthma or heart failure et al.) ;
5. Clear indication for anticoagulation therapy ( cardiac source of embolus);
6. Hemorrhagic tendency of any reason （including but not limit to Hemostatic disorder, platelet count \<100 × 109/L, history of drug-induced hepatic dysfunction）;
7. Any hemorrhagic transformation;
8. Gastrointestinal bleed or major surgery within 3 months of symptoms onset;
9. Stroke or TIA induced by interventional therapy or surgery;
10. Any upper extremity soft tissue, vascular injury or peripheral blood vessel disease which may contraindicate RIC;
11. Systolic blood pressure greater than 200 mmHg after medication;
12. Planned revascularization (any angioplasty or vascular surgery) within the next 3 months ；
13. Scheduled for surgery or interventional treatment requiring RIC cessation within next 3 months;
14. Severe noncardiovascular comorbidity with life expectancy \< 3 months;
15. Pregnancy;
16. Currently receiving an investigational drug or device by other studies.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
100 Years
Study:
NCT03004820
Study Brief:
Protocol Section:
NCT03004820